Abstract

Type 2 diabetes mellitus (T2DM) remains uncontrolled in a large number of patients despite advances in medical treatment. Bromocriptine mesylate is a quick release preparation of bromocriptine, which acts on hypothalamic pathways of glucose metabolism. It represents a novel therapeutic option in the management of T2DM. United States Food and Drug Administration in 2009 approved the use of bromocriptine mesylate in T2DM as an adjunct to diet and exercise. Various clinical trials have demonstrated the efficacy of bromocriptine mesylate in lowering glycosylated hemoglobin by 0.4 to 0.8% as monotherapy or add-on therapy with other antidiabetic agents. Action on central pathways affecting glucose metabolism makes it a great alternative to current modalities of treatment for T2DM.